Article
Japan’s revision of its three strategic documents reflects an intention to keep the United States engaged in the region while Japan fills any vacuums of U.S. power to preserve the Indo-Pacific order.
Ryo Sahashi
{
"authors": [
"Stephen Wertheim",
"Evan S. Medeiros",
"Vijay Gokhale"
],
"type": "legacyinthemedia",
"centerAffiliationAll": "dc",
"centers": [
"Carnegie Endowment for International Peace",
"Carnegie India"
],
"collections": [],
"englishNewsletterAll": "asia",
"nonEnglishNewsletterAll": "",
"primaryCenter": "Carnegie Endowment for International Peace",
"programAffiliation": "AP",
"programs": [
"Asia",
"American Statecraft"
],
"projects": [],
"regions": [
"North America",
"United States",
"East Asia",
"China"
],
"topics": [
"Democracy",
"Security",
"Military",
"Foreign Policy",
"Global Governance"
]
}
REQUIRED IMAGE
In The Media
Is U.S. Foreign Policy Too Hostile to China?
Experts weigh in on whether the United States is too hostile toward China.
Published on Oct 19, 2021
About the Authors
Stephen Wertheim
Senior Fellow, American Statecraft Program
Stephen Wertheim is a senior fellow in the American Statecraft Program at the Carnegie Endowment for International Peace.
Evan S. Medeiros
Nonresident Senior Fellow, Asia Program
Evan S. Medeiros is a nonresident senior fellow in the Asia Program at the Carnegie Endowment for International Peace.
Vijay Gokhale
Nonresident Senior Fellow, Carnegie India
Vijay Gokhale is a nonresident senior fellow at Carnegie India and the former foreign secretary of India. He has worked extensively on matters relating to the Indo-Pacific region with a special emphasis on Chinese politics and diplomacy.
Carnegie does not take institutional positions on public policy issues; the views represented herein are those of the author(s) and do not necessarily reflect the views of Carnegie, its staff, or its trustees.
More Work from Carnegie Endowment for International Peace
- The Two Logics Driving Japan’s Security Policy
- Caught in the Middle: Chinese Biotech Firms’ Divergent Responses to U.S. SanctionsCommentary
Chinese biotech companies have been on the receiving end of U.S. economic coercion. Yet their responses have differed significantly because firm and state interests are not uniformly aligned. For Washington, treating all Chinese tech firms the same, irrespective of their actual interests, risks pushing them farther into Beijing’s corner.
Xue Gong
- Inside the Global Race to Erode a Battery Manufacturing MonopolyCommentary
Over the past decade, China has moved from marginal player to major producer of all things batteries. The United States, Europe, and others are aiming to balance the market.
Milo McBride
- A Geothermal and Nuclear Strategy for the U.S. International Development Finance CorporationPaper
The DFC should focus on advanced, low-carbon energy sources, prioritizing areas where the United States has comparative advantages.
Noah Gordon, Liana Schmitter-Emerson
- Is the Russia-Ukraine War Vibe Shift Real?Commentary
Media coverage suggests Kyiv’s fortunes have changed. That shift may be important, but it only goes so far.
Dara Massicot, Aaron David Miller, Andrew S. Weiss
